News

Technology News

Sorbent Therapeutics Absorbs $36 Million New VC

Friday, July 1, 2011 5:37:00 AM PDT | VentureDeal Staff
   Sunnyvale, California  --  Biotechnology company Sorbent Therapeutics has secured $36 million in its second round of institutional venture capital financing.

Sorbent is developing "adaptable non-absorbed polymeric drugs" to treat congestive heart failure and other serious conditions.

Novartis Venture Fund led the round, which included previous investors Sofinnova Ventures, ARCH Venture Partners, CMEA Capital and AgeChem Venture Fund.

The company said it would use the financing to complete phase 2 trials for its lead candidate for heart failure, CLP1001.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1